(NASDAQ: CAPR) Capricor Therapeutics's forecast annual revenue growth rate of 80.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.42%.
Capricor Therapeutics's revenue in 2025 is $22,270,465.On average, 3 Wall Street analysts forecast CAPR's revenue for 2025 to be $1,812,568,724, with the lowest CAPR revenue forecast at $548,114,424, and the highest CAPR revenue forecast at $4,124,561,041. On average, 3 Wall Street analysts forecast CAPR's revenue for 2026 to be $2,739,201,834, with the lowest CAPR revenue forecast at $2,635,516,855, and the highest CAPR revenue forecast at $2,891,303,587.
In 2027, CAPR is forecast to generate $7,436,085,686 in revenue, with the lowest revenue forecast at $7,436,085,686 and the highest revenue forecast at $7,436,085,686.